Cerebrolysin

Cerebrolysin is a standardised peptide preparation produced by enzymatic breakdown of purified porcine brain proteins. It is one of the most heavily studied putative neurotrophic agents, with randomised trials in acute ischaemic stroke, vascular and Alzheimer-type dementia, and traumatic brain injury. The evidence base is large but mixed, and the compound remains a subject of active research rather than settled consensus.

What it is

Cerebrolysin is not a single molecule but a complex, standardised mixture of low-molecular-weight neuropeptides and free amino acids. It is manufactured by Ever Pharma (Unterach, Austria) through controlled enzymatic hydrolysis of lipid-free purified porcine (pig) brain protein. The finished preparation is characterised as roughly 85% free amino acids and about 15% biologically active peptides, all of which fall below a 10,000 Da (10 kDa) molecular-weight cut-off. Because there is no single defined sequence, Cerebrolysin has no discrete molecular formula or exact molecular mass; it is specified instead by its peptide fraction and manufacturing process.

The preparation is administered clinically as an aqueous solution given by intravenous or intramuscular injection, typically at doses of 10 to 50 mL per day in the trial literature. It sits in the class of peptide-based neurotrophic and neurorecovery agents. Supplied strictly for laboratory research use only, not for human or veterinary use.

How it works

The central hypothesis is that Cerebrolysin's small peptide fragments cross the blood-brain barrier and reproduce, in part, the actions of endogenous neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF). Preclinical work reports that the peptide fraction can engage tropomyosin receptor kinase (Trk) signalling, activating the PI3K/Akt survival pathway and the MAPK/ERK cascade. Downstream, PI3K/Akt signalling suppresses pro-apoptotic mediators and mitochondrial cytochrome c release, while ERK-driven CREB phosphorylation promotes transcription of genes involved in synaptic plasticity and long-term potentiation.

Beyond direct receptor mimicry, published mechanistic reviews describe effects on neurogenesis, angiogenesis, synaptic remodelling, modulation of neuroinflammation, and interaction with amyloid-precursor-protein processing and tau pathology relevant to Alzheimer-type disease. These pathways are proposed to underlie the neuroprotective (acute injury) and neurorecovery (rehabilitation phase) effects tested in the clinical programme. It should be stressed that the exact active constituents remain incompletely defined, which is a recurring limitation noted by independent reviewers.

What the research shows

Cerebrolysin has been evaluated in dozens of randomised, double-blind, placebo-controlled trials. The signal is strongest and most consistent for motor and functional recovery after stroke when combined with rehabilitation, moderate for cognitive endpoints in mild-to-moderate dementia, and more equivocal at the level of hard outcomes such as death, where independent Cochrane analysis found no clear benefit. The headline figures below are drawn directly from the primary trial and meta-analysis literature.

Safety signals in the literature

In the CARS stroke trial, treatment-emergent adverse events were similar between groups (69.2% Cerebrolysin versus 71.2% placebo) and serious adverse events were numerically fewer with Cerebrolysin (2.9% versus 6.7%); the authors judged it safe and well tolerated. The 14-trial stroke meta-analysis likewise found no significant difference in serious adverse events (RR 1.08, 95% CI 0.84-1.40) or mortality (RR 0.86, 95% CI 0.68-1.09). Against this, the Cochrane review cautioned that pooled data suggest Cerebrolysin might cause a higher rate of spontaneous adverse events requiring hospitalisation, underscoring why independent replication continues to matter.

Side Effects

Unlike many research peptides, Cerebrolysin has decades of real clinical data from the countries where Ever Pharma has marketed it for stroke, dementia, and traumatic brain injury. Reported adverse effects are mostly mild and transient, and a recurring theme in the product information is that giving the infusion too quickly is what provokes many of them. The reactions below come from prescribing information, published case reports, and Cochrane systematic reviews.

Overall, Cerebrolysin is generally well tolerated in the clinical literature, and the Cochrane vascular dementia review found no difference in rates of adverse effects versus placebo (RR 0.91, 95% CI 0.29 to 2.85, very low-quality evidence), while the stroke review found little to no difference in the total number of people with serious adverse events. The main hard limits are its contraindications: known hypersensitivity, status epilepticus, and severe renal impairment, with added caution in anyone who has epilepsy. See the Cochrane vascular dementia review for the full safety analysis.

At a glance

Dosing

In the countries where Cerebrolysin is approved, it is given as an intravenous or intramuscular infusion in defined courses rather than as a single dose, with the daily volume varying by indication. Reported clinical regimens typically run from about 10 mL to 50 mL per day over courses of 10 to 30 treatment days, often repeated in cycles. The figures below come from published randomized trials in stroke, dementia, and traumatic brain injury. They describe the doses studied in those settings and are not instructions for use.

Across these indications the pattern is a daily course of 10 to 30 treatment days, frequently repeated in cycles after a treatment-free interval. Cerebrolysin is not approved by the US FDA, and none of the above is a dosing recommendation. This information is educational and framed for laboratory research use only.

Preparing it

Where Cerebrolysin is supplied as a lyophilised research vial rather than a ready-made solution, it is reconstituted with bacteriostatic or sterile water before use. See the reconstitution guide for step-by-step handling and the concentration guide for working out volume per unit of peptide. Solutions are typically kept refrigerated at 2-8 C and shielded from light. This handling note is provided for laboratory research use only.

Where to go next

Last updated on July 3, 2026